Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DaxorFRA:DX5 -3.66%51 EV-to-FCF is 103.92 as of Aug. 29, 2026. GuruFocus rates FRA:DX5 with a GF Score™ of 51/100 and a GF Value™ of €29.07 (Possible Value Trap). The stock has 1 warning sign investors should review. Among 409 Medical Devices & Instruments companies, Daxor ranks worse than 88.26% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Daxor's Enterprise Value is €51.34 Mil.
Daxor's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €0.49 Mil. Therefore, Daxor's EV-to-FCF for today is 103.92.
The historical rank and industry rank for Daxor's EV-to-FCF or its related term are showing as below:
FRA:DX5'
s EV-to-FCF Range Over the Past 10 Years
Min: -67.98 Med: -13.66 Max: 2618.55
Current: 104.75
During the past 13 years, the highest EV-to-FCF of Daxor was 2618.55. The lowest was -67.98. And the median was -13.66.
FRA:DX5's EV-to-FCF is ranked worse than 88.26% of 409
companies
in the Medical Devices & Instruments industry
Industry Median: 24.74
vs FRA:DX5: 104.75
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
As of today (2026-08-29), Daxor's stock price is €7.90.
Daxor's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €1.399. Therefore, Daxor's PE Ratio (TTM) for today is 5.65.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Daxor's share price for today is €7.90.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Daxor's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €1.399.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Daxor EV-to-FCF Related Terms
Daxor EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Daxor's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Daxor's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Daxor EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Daxor's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Daxor's EV-to-FCF falls into.
Daxor's current Enterprise Value is €51.34 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Daxor's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €0.49 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Daxor (FRA:DX5) has a EV-to-FCF of 103.92 as of Aug. 29, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Daxor and its competitors. According to the industry distribution chart, Daxor ranks #361 out of 409 companies in the Medical Devices & Instruments industry, placing it in the top 88.3%.
Is Daxor's EV-to-FCF too high?
Daxor's current EV-to-FCF is 103.92. The Medical Devices & Instruments industry median EV-to-FCF is 24.74. Daxor's value of 103.92 is 320% above this industry median. Based on the distribution chart, Daxor ranks #361 out of 409 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Daxor has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Daxor's EV-to-FCF compare to POCI and NEPH?
According to the Medical Devices & Instruments industry distribution chart, Daxor ranks #361 out of 409 companies for EV-to-FCF. This places Daxor in the lower half of its industry. The industry median EV-to-FCF is 24.74. Daxor's value of 103.92 is 320% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 24.74, based on 409 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Daxor's current EV-to-FCF of 103.92 is 320% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Daxor and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 24.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Daxor's current EV-to-FCF is 103.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Daxor stock overvalued right now?
Based on GuruFocus' analysis, Daxor (FRA:DX5) is currently considered Possible Value Trap. The stock's GF Value™ is €29.07, compared to a current price of €7.90 — trading 72.8% below its estimated fair value. The current EV-to-FCF is 103.92 and 320% above the Medical Devices & Instruments industry median of 24.74. Daxor's overall GF Score™ is 51/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Daxor (FRA:DX5), the current EV-to-FCF is 103.92 as of Aug. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Daxor (FRA:DX5) Overvalued in 2026?
Based on GuruFocus' analysis, Daxor stock appears to be undervalued.
The current stock price of €7.90 is trading 72.8% below its estimated GF Value™ of €29.07.
GuruFocus considers Daxor to be Possible Value Trap.
Key valuation signals for FRA:DX5:
EV-to-FCF: 103.92
GF Value™: €29.07 vs. price of €7.90 (72.8% below fair value)
Industry Position: 320% above the Medical Devices & Instruments median (#361 of 409)
No single metric tells the full story. See the FRA:DX5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system.
51GF Score
Get the complete analysis for FRA:DX5
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:DX5 has been successfully added to your 
